Kodiak Sciences (KOD) Competitors $4.74 -0.07 (-1.46%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$4.76 +0.02 (+0.42%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KOD vs. PROK, COLL, AKBA, AMPH, RCUS, DYN, SYRE, VERV, AVXL, and MLYSShould you be buying Kodiak Sciences stock or one of its competitors? The main competitors of Kodiak Sciences include ProKidney (PROK), Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Amphastar Pharmaceuticals (AMPH), Arcus Biosciences (RCUS), Dyne Therapeutics (DYN), Spyre Therapeutics (SYRE), Verve Therapeutics (VERV), Anavex Life Sciences (AVXL), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. Kodiak Sciences vs. Its Competitors ProKidney Collegium Pharmaceutical Akebia Therapeutics Amphastar Pharmaceuticals Arcus Biosciences Dyne Therapeutics Spyre Therapeutics Verve Therapeutics Anavex Life Sciences Mineralys Therapeutics Kodiak Sciences (NASDAQ:KOD) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability. Does the media refer more to KOD or PROK? In the previous week, ProKidney had 16 more articles in the media than Kodiak Sciences. MarketBeat recorded 21 mentions for ProKidney and 5 mentions for Kodiak Sciences. ProKidney's average media sentiment score of 0.63 beat Kodiak Sciences' score of 0.51 indicating that ProKidney is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProKidney 8 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, KOD or PROK? ProKidney has higher revenue and earnings than Kodiak Sciences. ProKidney is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKodiak SciencesN/AN/A-$176.21M-$3.63-1.31ProKidney$80K13,647.14-$61.19M-$0.60-6.22 Is KOD or PROK more profitable? ProKidney's return on equity of 0.00% beat Kodiak Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Kodiak SciencesN/A -115.71% -54.17% ProKidney N/A N/A -15.03% Do analysts recommend KOD or PROK? Kodiak Sciences currently has a consensus target price of $9.00, suggesting a potential upside of 89.87%. ProKidney has a consensus target price of $6.25, suggesting a potential upside of 67.56%. Given Kodiak Sciences' higher possible upside, research analysts plainly believe Kodiak Sciences is more favorable than ProKidney.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kodiak Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00ProKidney 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has more volatility & risk, KOD or PROK? Kodiak Sciences has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Do institutionals and insiders have more ownership in KOD or PROK? 89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 45.9% of Kodiak Sciences shares are held by insiders. Comparatively, 41.5% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryProKidney beats Kodiak Sciences on 9 of the 14 factors compared between the two stocks. Get Kodiak Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KOD vs. The Competition Export to ExcelMetricKodiak SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$253.79M$2.90B$5.51B$9.31BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-1.3120.3628.1219.69Price / SalesN/A298.74439.46100.25Price / CashN/A42.3835.5357.53Price / Book1.667.768.235.67Net Income-$176.21M-$55.11M$3.23B$257.51M7 Day Performance5.57%0.19%-0.52%-0.16%1 Month Performance33.52%10.80%6.71%9.89%1 Year Performance57.48%-0.68%27.10%15.08% Kodiak Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KODKodiak Sciences4.0332 of 5 stars$4.74-1.5%$9.00+89.9%+46.3%$253.79MN/A-1.3190PROKProKidney3.3495 of 5 stars$3.69-18.7%$5.67+53.6%+54.8%$1.08B$306K-6.153Trending NewsAnalyst ForecastHigh Trading VolumeCOLLCollegium Pharmaceutical4.4029 of 5 stars$32.83+1.0%$43.75+33.3%-0.6%$1.05B$631.45M26.91210Positive NewsBuyback AnnouncementAKBAAkebia Therapeutics3.6947 of 5 stars$3.97+1.0%$6.75+70.0%+174.6%$1.04B$160.18M-18.90430AMPHAmphastar Pharmaceuticals4.2947 of 5 stars$21.95+1.3%$32.33+47.3%-46.3%$1.03B$731.97M7.952,028RCUSArcus Biosciences2.3171 of 5 stars$9.66+3.5%$21.29+120.5%-41.7%$1.02B$258M-2.30500DYNDyne Therapeutics3.8783 of 5 stars$8.91+3.1%$41.13+361.6%-78.9%$1.01BN/A-2.48100Trending NewsAnalyst ForecastInsider TradeGap UpSYRESpyre Therapeutics1.8782 of 5 stars$16.41+4.6%$53.40+225.4%-47.7%$989.20M$890K-4.3573News CoverageVERVVerve Therapeutics2.8671 of 5 stars$11.03flat$14.57+32.1%+40.2%$983.25M$59.61M-5.23110AVXLAnavex Life Sciences3.9118 of 5 stars$11.48+3.3%$44.00+283.3%+93.1%$980.05MN/A-20.8740MLYSMineralys Therapeutics2.1853 of 5 stars$15.02+3.7%$32.25+114.7%-1.8%$979.00MN/A-4.0328Positive NewsInsider TradeGap Down Related Companies and Tools Related Companies PROK Competitors COLL Competitors AKBA Competitors AMPH Competitors RCUS Competitors DYN Competitors SYRE Competitors VERV Competitors AVXL Competitors MLYS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KOD) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kodiak Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kodiak Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KOD Stock Alerts